Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Already Seeking Stribild Successor, Going Solo On Key HCV Combo

This article was originally published in The Pink Sheet Daily

Executive Summary

Just weeks after the apparently successful launch of its HIV “quad pill,” Gilead already is talking up a new compound with potential as part of an HIV combination therapy. And in HCV, the company is preparing a new study without partner Bristol-Myers Squibb.

You may also be interested in...



In Brief: FDA Panel Rejects Novartis’ Panobinostat, Gilead Files Stribild Successor

Also, agency tells AEterna Zentaris its growth hormone deficiency drug Macrilen requires a new confirmatory trial, and privately held Spriaso announces FDA acceptance of NDA for Rinotuss12, a solid oral dose cough/cold product combining codeine and chlorpheniramine.

Drug Launches: Is It Better To Be The Tortoise Or The Hare?

As companies present their third quarter earnings they discuss the drugs that they’ve launched over the last quarter – some have had success right out of the gate, while others hope to build momentum, albeit more slowly.

As AbbVie Prepares To Launch, Some Wind Gets Knocked Out Of Its Sails

Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel